Mountain View, CA, United States
Mountain View, CA, United States
SEARCH FILTERS
Time filter
Source Type

News Article | April 20, 2017
Site: marketersmedia.com

Wiseguyreports.Com Adds “Bioinformatics -Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022” To Its Research Database This report studies the global Bioinformatics market, analyzes and research the Bioinformatics development status and forecast in USA, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Market segment by Type, Bioinformatics can be split into Knowledge Management Tools Bioinformatics Platforms Bioinformatics Services Market segment by Application, Bioinformatics can be split into Genomics Chemoinformatics and Drug Design Proteomics Transcriptomics Metabolomics Molecular Phylogenetics Others Global Bioinformatics Market by Players, Regions, Type and Application, Forecast to 2022 1 Industry Overview 1.1 Bioinformatics Market Overview 1.1.1 Bioinformatics Product Scope 1.1.2 Market Status and Outlook 1.2 Global Bioinformatics Market Size and Analysis by Regions 1.2.1 USA 1.2.2 EU 1.2.3 Japan 1.2.4 China 1.2.5 India 1.2.6 Southeast Asia 1.3 Digital Out of Home Market by Type 1.3.1 Knowledge Management Tools 1.3.2 Bioinformatics Platforms 1.3.3 Bioinformatics Services 1.4 Bioinformatics Market by End Users/Application 3 Company (Top Players) Profiles 3.1 DNAnexus 3.1.1 Company Profile 3.1.2 Main Business/Business Overview 3.1.3 Products, Services and Solutions 3.1.4 Bioinformatics Revenue (Value) 2012-2017 3.1.5 Recent Developments 3.2 ID Business Solutions 3.2.1 Company Profile 3.2.2 Main Business/Business Overview 3.2.3 Products, Services and Solutions 3.2.4 Bioinformatics Revenue (Value) 2012-2017 3.2.5 Recent Developments 3.3 Perkinelmer 3.3.1 Company Profile 3.3.2 Main Business/Business Overview 3.3.3 Products, Services and Solutions 3.3.4 Bioinformatics Revenue (Value) 2012-2017 3.3.5 Recent Developments 3.4 Waters Corporation 3.4.1 Company Profile 3.4.2 Main Business/Business Overview 3.4.3 Products, Services and Solutions 3.4.4 Bioinformatics Revenue (Value) 2012-2017 3.4.5 Recent Developments 3.5 Illumina 3.5.1 Company Profile 3.5.2 Main Business/Business Overview 3.5.3 Products, Services and Solutions 3.5.4 Bioinformatics Revenue (Value) 2012-2017 3.5.5 Recent Developments 3.6 Thermo Fisher Scientific 3.6.1 Company Profile 3.6.2 Main Business/Business Overview 3.6.3 Products, Services and Solutions 3.6.4 Bioinformatics Revenue (Value) 2012-2017 3.6.5 Recent Developments 3.7 Qiagen 3.7.1 Company Profile 3.7.2 Main Business/Business Overview 3.7.3 Products, Services and Solutions 3.7.4 Bioinformatics Revenue (Value) 2012-2017 3.7.5 Recent Developments 3.8 Agilent Technologies 3.8.1 Company Profile 3.8.2 Main Business/Business Overview 3.8.3 Products, Services and Solutions 3.8.4 Bioinformatics Revenue (Value) 2012-2017 3.8.5 Recent Developments 3.9 Applied Biological Materials (ABM) 3.9.1 Company Profile 3.9.2 Main Business/Business Overview 3.9.3 Products, Services and Solutions 3.9.4 Bioinformatics Revenue (Value) 2012-2017 3.9.5 Recent Developments 3.10 Biomax Informatics 3.10.1 Company Profile 3.10.2 Main Business/Business Overview 3.10.3 Products, Services and Solutions 3.10.4 Bioinformatics Revenue (Value) 2012-2017 3.10.5 Recent Developments ... For more information, please visit https://www.wiseguyreports.com/sample-request/1203914-global-bioinformatics-market-by-players-regions-type-and-application-forecast-to


MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--DNAnexus, the global leader in genome informatics and data management, announced that Rady Children’s Institute for Genomic Medicine (RCIGM) in San Diego has adopted the DNAnexus Platform to enable the world’s fastest whole genome data analysis pipeline for pediatric care settings. The work is part of a National Institute of Health (NIH) research program led by Stephen Kingsmore, MD, DSc, President and CEO of RCIGM. RCIGM plans to expand this integrated solution to partners nationally, fostering a growing genomic database that healthcare providers can access to quickly diagnose rare disease in children. DNAnexus is facilitating this goal by providing a flexible and scalable platform for local and distributed sequencing and analysis and enabling a highly optimized end-to-end rapid whole genome solution. At RCIGM, the platform is also being used to securely bank genomic data, work with collaborators and integrate with the Institute’s custom portal and big-data platform. The Institute’s integrated process spans genomic phenotyping through to interpretation of results and allows for data aggregation and synthesis to improve diagnosis, semi-automate reporting and to establish metrics for diagnostic and clinical utility. “Our goal is to ensure that genome-powered precision medicine is available to every child who needs it. To do this, building a research-to-bedside pipeline at a single hospital isn’t enough. We needed a solution that can be scaled up and is accessible anywhere in the world,” said Dr. Kingsmore. “DNAnexus has the technology and expertise to facilitate this ambitious project, allowing us to collaborate in a secure environment.” The NIH Newborn Sequencing In Genomic Medicine and Public Health program addresses how genomic sequencing can replicate or augment known screening results for newborn disorders, what knowledge sequencing can provide for conditions not currently screened, and what additional information could be learned from sequencing relevant to the clinical care of newborns. The NSIGHT program is funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Human Genome Research Institute components of the National Institutes of Health. "Rady Children’s Institute for Genomic Medicine is a pioneer in the use of genomic data to drive better outcomes for children with inherited diseases, and we are proud to support this cutting-edge work led by Dr. Kingsmore,” said Richard Daly, CEO of DNAnexus. “DNAnexus serves as a secure and compliant network supporting multiple locations and enabling providers such as Rady with the technical platform to expand their network and data analysis capacity globally and in a cost-effective manner.” The Institute is leading the way in advancing precision pediatric medicine by combining ultra-rapid whole genome sequencing with expert analysis and interpretation to speed diagnosis of genetic disease. Research conducted at RCIGM is being used to improve care of critically ill newborns at Rady Children’s Hospital-San Diego. Learn more at www.RadyGenomics.org Rady Children's Hospital-San Diego is a 551-bed pediatric care facility providing the largest source of comprehensive pediatric medical services in San Diego, Southern Riverside and Imperial counties. Rady Children's is the only hospital in the San Diego area dedicated exclusively to pediatric healthcare and is the region's only designated pediatric trauma center. In June 2016, U.S. News & World Report ranked Rady Children's among the best children's hospitals in the nation in nine pediatric specialties the magazine surveyed. Rady Children's is a nonprofit organization that relies on donations to support its mission. For more information, visit www.rchsd.org and find us on Facebook, Twitter and Vimeo. DNAnexus combines expertise in computing and bioinformatics to create the global network for genomics, operating in North America, Europe, Asia-Pacific (including China), South America, and Africa. The secure, scalable, and collaborative DNAnexus Platform helps thousands of researchers across a spectrum of industries – biopharmaceutical, bioagricultural, sequencing services, clinical diagnostics, government, and research consortia – accelerate their genomics programs globally. For more information on DNAnexus, please visit www.dnanexus.com or follow the company @DNAnexus.


News Article | May 23, 2017
Site: www.businesswire.com

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--DNAnexus, Inc., the global leader in genome informatics and data management, today announced that its secure cloud-based platform has been selected as a partner for AstraZeneca’s Centre for Genomics Research (CGR), which will analyse over two million genomes in the next 10 years to inform drug discovery and development. Financial terms of the collaboration were not disclosed. The AstraZeneca Centre for Genomics Research is building a bespoke database of genomic sequences from samples donated by patients in its global clinical trials over the past 15 years and over the next 10 years, integrated with associated clinical and drug response data. “Investing in genomics is critical to our continued innovation here at AstraZeneca,” said Ruth March, Vice President Personalised Healthcare and Biomarkers. “The DNAnexus Platform offers a secure, scalable solution that both serves our needs in this pivotal area today and allows us to continue progressing towards our ambitious goal of analysing two million genomes to help us better understand the underlying causes of disease. We look forward to working with DNAnexus to advance the future of personalised healthcare and develop the most innovative and impactful treatments for patients.” “The Centre for Genomics Research has established an unprecedented goal of sequencing two million genomes over the course of 10 years, and DNAnexus is pleased to support this important initiative,” said Richard Daly, chief executive officer of DNAnexus. “AstraZeneca is making significant strides towards changing the future of research and development across multiple disease areas, and we are excited to work with our partner to help build their drug discovery and development solution.” DNAnexus combines expertise in computing and bioinformatics to create the global network for genomics, operating in North America, Europe, Asia-Pacific (including China), South America, and Africa. The secure, scalable, and collaborative DNAnexus Platform helps thousands of researchers across a spectrum of industries – biopharmaceutical, bioagricultural, sequencing services, clinical diagnostics, government, and research consortia – accelerate their genomics programs globally. For more information on DNAnexus, please visit www.dnanexus.com or follow the company @DNAnexus. Biomedical datasets are scaling exponentially and extracting insights from multiple data types has added to the increasing challenge. To address this issue, the DNAnexus translational informatics platform allows the CGR to analyze a massive volume of raw sequencing data rapidly and economically, enabling the processing of samples from thousands of patients per week and the sharing of data easily and safely with collaborators around the world. The platform also provides a secure environment where genetic data can be combined with de-identified clinical data, paving the way for novel scientific insights.


News Article | June 27, 2017
Site: www.businesswire.com

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--DNAnexus, Inc., the global leader in genome informatics and data management, today announced the launch of the MOSAIC Microbiome Platform in collaboration with Janssen Research & Development, LLC and its Janssen Human Microbiome Institute (JHMI). The cloud-based platform, which is powered by DNAnexus, provides a secure environment for scientists around the world to collaborate on research, share data and advance methods aimed at increasing understanding of the human microbiome, while accelerating the translation of these insights into healthcare solutions. Affordable next-generation sequencing technologies have transformed microbiome research, resulting in huge volumes of microbiome-generated data that require advanced computational methods and scalable computational power for their interpretation and analysis. MOSAIC enables scientists to store and manage these datasets securely and efficiently, and to customize workflows for analyses while collaborating with other users to contribute to microbiome science and standards. “We are proud to help build a vibrant research community inspiring open collaboration and advancement in microbiome-based health solutions,” said Richard Daly, Chief Executive Officer of DNAnexus. “Understanding the metagenomic data associated with the microbiome is a complex and ambitious undertaking that the DNAnexus MOSAIC Platform is well-suited to support. We look forward to working with the global community of scientists committed to finding new microbiome-based solutions with the potential to transform human health.” To encourage and foster global collaboration focused on advancing the creation of new methods and standards around this emerging area of science, a series of community challenges will be hosted through MOSAIC. Once a challenge is launched, scientists working anywhere in the world can contribute their tools, data, ideas and other resources. MOSAIC is intended to serve as a virtual ecosystem and innovation accelerator for the entire microbiome community, including academic centers, biotech and pharmaceutical companies, as well as life science technology developers and regulatory agencies, in order to collectively advance this rapidly growing field. MOSAIC, and the first microbiome challenge, will launch and open to participants in the coming months. Those interested in joining the MOSAIC community and participating in the challenges are encouraged to visit www.mosaicbiome.com to learn more. Challenges will address a variety of important topics, including advancing strain-level microbial profiling methods of human samples. DNAnexus combines expertise in computing and bioinformatics to create the global network for genomics, operating in North America, Europe, Asia-Pacific (including China), South America, and Africa. The secure, scalable, and collaborative DNAnexus Platform helps thousands of researchers across a spectrum of industries – biopharmaceutical, bioagricultural, sequencing services, clinical diagnostics, government, and research consortia – accelerate their genomics programs globally. For more information on DNAnexus, please visit www.dnanexus.com or follow the company @DNAnexus.


News Article | June 21, 2017
Site: www.prnewswire.com

NEW YORK, June 21, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Genetic Testing in US$ Million. The US market is further analyzed by the following Segments: Prenatal & Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Diagnostics. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 88 companies including many key and niche players such as - Read the full report: http://www.reportlinker.com/p02284877/Genetic-Testing.html 23andMe, Inc. Abbott Laboratories AutoGenomics, Inc. Biocartis NV BioRad Laboratories Read the full report: http://www.reportlinker.com/p02284877/Genetic-Testing.html I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations Disclaimers Data Interpretation & Reporting Level Quantitative Techniques & Analytics Product Definitions and Scope of Study Prenatal Diagnosis and Newborn Genetic Testing Pharmacogenetics/Pharmacogenomics Predictive Diagnostics II. EXECUTIVE SUMMARY 1. GLOBAL MARKET OVERVIEW A Curtain Raiser Top Ten Genetic Disorders Worldwide Genetic Testing: Heralding a New Era Genetic Testing Paves the Way for Personalized Medicine Table 1: Drug Ineffectiveness for Select Therapeutic Categories - Necessitating Personalized Medicine (includes corresponding Graph/Chart) Genetic Testing - A Critical Part of the Rapidly Developing In-Vitro Diagnostics (IVD) Market Table 2: Global In Vitro Diagnostics (IVD) Market by Geographic Region (2016): Percentage Breakdown of Revenues for Asia-Pacific; Europe, Middle-East and Africa; North America; and Latin America (includes corresponding Graph/Chart) Table 3: Global In-Vitro Diagnostics Market by Sector (2016): Percentage Breakdown of Revenues for Hospital & Commercial Laboratories, and Decentralized & Patient Self-Testing (includes corresponding Graph/Chart) Table 4: Leading Players in the Global In Vitro Diagnostics Market (2016): Percentage Breakdown of Revenues for Abbott, Beckman Coulter, Roche, Siemens, Thermo Fisher and Others (includes corresponding Graph/Chart) Genetic Testing: The Rapidly Growing Segment of Molecular Diagnostics Market Table 5: Global Molecular Diagnostics Market (2016): Percentage Breakdown of Revenues for Blood Donor Screening, Genomics and Infectious Disease Testing (includes corresponding Graph/Chart) An Overview of Current Technologies in Genetic Testing Table 6: Global Genetic Testing Market by Technology (2016 & 2024): Percentage Breakdown of Revenue for Hybridization, Microarray, NGS and PCR (includes corresponding Graph/Chart) Biomarker Discovery Leads to Advanced Genetic Testing List of US-FDA Approved Biomarkers for Cancer Ballooning Global Population Offers Increased Growth Opportunities Table 7: Top 25 Countries Worldwide in Terms of Population: 2015 & 2016 (includes corresponding Graph/Chart) Aging Population Drives the Genetic Testing Market Table 8: Global Population Statistics for the 65+ Age Group (2015) (includes corresponding Graph/Chart) Table 9: Comparison of Aging Population by Country (1980, 2015 & 2050): Percentage Share of Population Aged Above-65 Years of the Overall Population for Select Countries (includes corresponding Graph/Chart) Table 10: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart) Improving Healthcare Expenditure to Drive Demand Table 11: Healthcare Spending as % of GDP by Region (2016E) (includes corresponding Graph/Chart) Table 12: Per-Capita Healthcare Expenditure in US$ for Select Countries/Regions (2014) (includes corresponding Graph/Chart) Competitive Overview 2. SEGMENTAL REVIEW Prenatal Testing Market to Rise List of Genetic Disorders by Event, Genetic Manifestation and Prevalence Prenatal Testing - Changing the World of Pregnancy Care Prenatal Testing - A Rudimentary Overview List of Available Prenatal Screening and Diagnostic Tests by Indication Conventional Invasive Pre-Natal Diagnostic Techniques - A Risky Affair Other Negativities of Existing Invasive Techniques Emergence of Non-Invasive Prenatal Diagnosis (NIPD) US Leads in NIPD Market Competition Intensifies in the NIPD Market Commercially Available NIPD (Genetic) Tests for Aneuploidy in the US NIPD Eliminates Risks and Uncertainty of Conventional Diagnostic Procedures Opposition to NIPD Technique - A Significant Hurdle to Adoption Benefits Outweigh Snags in NIPD Tests Major Factors Influencing Penetration of NIPD Tests Table 13: Price Comparison of Existing Tests and Screening Procedures for Down's Syndrome Diversity in NIPD Usage on the Cards Expanded Newborn Screening Technological Advancements Boost Prenatal Genetic Screening Market CMA Stakes Claim as the First-Line Test in Fetal Abnormalities; Issues Hinder Growth Strain on Resources Prevent Wide Adoption of Expanded Carrier Sequencing Fetal Diagnostic WES - A Promising Advancement in Prenatal Screening Predictive Diagnostics Breast Cancer Gene Testing Market to Expand Strongly Myriad Genetics - The Unquestioned Leader in Breast Cancer Testing Routine Clinical Testing Vs. Predictive Genetic Testing Increasing Incidence and Prevalence of CDDs: A Major Growth Driver Discovery of Novel Biomarkers Crucial to Predictive Diagnostics Unresolved Issues Hamper Widespread Implementation of Genetic Diagnosis and Testing for Monogenetic Disease Dearth of Genetic Counselors - A Major Hurdle for the Predictive Genetic Testing Pharmacogenomics Development Augurs Growth of Genetic Testing Market 3. MARKET TRENDS Direct-to-Consumer Genetic Testing - A Key Trend in the Genetic Testing Market Direct-to-Consumer Genetic Testing is Here to Stay Creating a Platform for New Companies Business Models for DTC Genetic Testing Firms Growing Prominence of DTC Genetic Testing: A Boon or a Curse? Genetic Screening of Newborns to Rise Pre-implantation Genetic Diagnosis (PGD) - A Major Driver for the Genetic Testing Market Whole Genome Sequencing - Boon or Bane to Genetic Testing? Utility of Genetic Testing for Warfarin Study As Technologies Grow, Need for Better Interpretation of Tests Increases Selling Collected Patient Genetic Information Becomes a New Business Oncology - A Key Focus Area for Genetic Testing Table 14: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported (in Thousands) for Asia-Oceania, Europe, North America, Latin America & The Caribbean, and Africa (includes corresponding Graph/Chart) Table 15: New Cancer Cases in the World by Affected Site (2012) (in Thousands) (includes corresponding Graph/Chart) Table 16: Cancer Incidence in Developed Nations by Site: 2012 (includes corresponding Graph/Chart) Table 17: Global Incidence of Common Cancers in Men (2012): Number of New Cases Reported in Thousands for Lung & Bronchus, Prostate, Colorectal, and Liver Cancers (includes corresponding Graph/Chart) Table 18: Global Incidence of Common Cancers in Women (2012): Number of New Cases Reported in Thousands for Breast, Colorectal, Lung & Bronchus, and Liver Cancers (includes corresponding Graph/Chart) Table 19: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer-Related Deaths (in Thousands) for Asia-Oceania, Europe, North America, Latin America & The Caribbean, and Africa (includes corresponding Graph/Chart) Liquid Biopsy to Change the Face of Cancer Diagnosis and Treatment Genetic Testing May Aid CNS Disease Therapeutics Neurodegenerative Diseases - Major Focus Area for Genetic Testing Alzheimer's Disease Validity of Emerging Genetic Tests for Alzheimer's Newly Developed Test Predicts Age of Onset of Alzheimer's Huntington's Disease Table 20: Global Prevalence of Huntington's Disease by Geographic Region (includes corresponding Graph/Chart) Genetic Testing - An Indispensable Tool for Cystic Fibrosis Table 21: Most Common Mutations and Worldwide Frequency (includes corresponding Graph/Chart) Histocompatibility Testing Next-Generation Sequencing - A Giant Leap in Genome Sequencing Pediatric Genetic Testing for Screening Adult Onset Disorders Fast Gaining Acceptance Better Regulatory Safeguards Required for Global Genetic Testing Industry Challenges Faced Controversial Applications Marr Genetic Testing Market Genetic Counseling: Gaining Momentum Online Approach Gains Momentum Recommendations of ACOG and ACGM Augments Demand for Cystic Fibrosis Testing Ethical Issues & Need for Appropriate Regulating Policies Issues Related to Genetic Tests for Obesity Diagnosis and Treatment during Pregnancy - An Effective Way of Alleviating Syphilis Related Deaths and Stillbirths 4. MOLECULAR DIAGNOSTICS MARKET - AN INSIGHT Global Molecular Diagnostics on a High Growth Curve Automation Driving Global Market Molecular Diagnostics: Marking the Convergence of Numerous Technologies MDx Market for Infectious Diseases Zooming Ahead Aging Population, Disease Incidence - Fundamental Drivers of Growth Pharmaceutical Firms Carving Their Niche in Molecular Diagnostics Market Towards Tailoring the Right Treatment for the Right Disease Limited Reimbursements by Third Party Payers - A Stumbling Block Disease-Specific Molecular Diagnostics to Deliver Improved Clinical Outcomes Molecular Diagnostics and Intellectual Property Business Opportunities in the Offing Medical Training and Practice Challenges Hurdles All the Way for Companies Eyeing Molecular Diagnostics Product Marketing - Key to Commercial Success Integration of Molecular Diagnostics into Therapeutics Molecular Diagnostics - Moving from Centralization to Decentralization Competitive Landscape of the Molecular Diagnostics Market Table 22: Leading Players in the Global Molecular Diagnostics Market (2016): Percentage Breakdown of Value Sales for Abbott, Cepheid, Grifols, Hologic, Qiagen, Roche and Others (includes corresponding Graph/Chart) New Entrants Eye Unmet Needs 5. PRODUCT OVERVIEW Preface to Genetic Testing Genetic Testing and its Applications Gene Candidate and Genome Screen 'DNA Chip' to Chip into Genetic Field Techniques Used to Identify Changes in Genes Types of Genetic Testing Prenatal Diagnosis Cancer Testing Carrier Identification Newborn Screening Predictive Testing Pre-Symptomatic Testing Cytogenetic Tests Steps in Genetic Testing Process Limitations Risks and Other Limitations of Genetic Testing Medical Institutions to Reap the Benefit of Genetic Testing Pharmacogenetics/Pharmacogenomics Review of Select Genetic Tests Cystic Fibrosis Breast and Ovarian Cancer (BRCA) Alzheimer's disease Colorectal Cancer Haemochromatosis (HH) Cowden Syndrome Huntington's disease (HD) Costs of Select Tests Table 23: Costs of Select Genetic Tests Genetic Testing Techniques Signal Amplification Technologies PCR - New Developments Quantitative Real-Time PCR for Molecular Diagnostics Signal Detection and Quantification Quantitative Real-Time RT-PCR Analysis Applications of Quantitative Real-Time PCR Analysis Viral Detection and Viral-Load Monitoring Sensitive Detection of Infectious Disease Agents Predisposition Testing Non-PCR Methods Other Signal Amplification Technologies DNA Probe Based Products Direct Detection of Specific Nucleic Acid Sequences Nucleic Acid Amplification and Detection DNA Sequencing and Gene Detection Arrays of Immobilized Probes (DNA Chips) in Gene Detection RNA Diagnostics 6. PRODUCT LAUNCHES/INNOVATIONS AutoGenomics Rolls Out INFINITI® H. pylori Assay 23andMe Obtains FDA Approval for Personal Genetic Test for Select Diseases Invitae Adds News Tests to Proactive Genetic Testing Repertoire Thermo Fisher Scientific Launches CarrierScan™ Assay MedGenome Unveils Claria Carrier Screening Test in India Phosphorus Rolls Out Advances Tests for Inherited Conditions Cancer Genetics Launches Genomic Panel for HBOC Illumina, Bio-Rad Launch Single-Cell Genomic Sequencing Solution MyHeritage Introduces MyHeritage DNA Service Thermo Fisher Scientific Unveils Clariom Pico Assays IBM Watson Health, Quest Diagnostics Roll Out IBM Watson Genomics Thermo Fisher Scientific Introduces PharmacoScan Solution Good Start Genetics Launches EmbryVu PGS Test Spark Therapeutics Introduces Testing for Inherited Retinal Diseases AutoGenomics Launches INFINITI® Buccal Sample Collection Kit FutuTest Launches FERTIFY™ Genetic Test Quest Diagnostics Introduces New Cancer Test Services Good Start Genetics Launches Next-Generation Embryo Screening Solution Invitae Introduces Pediatric Tests for Rare Disease and Pediatric Genetics Contextual Genomics Introduces Cancer Genome Test Transgenomic Introduces CMT NGS Panel Ambry Genetics Rolls Out Suite of Genetic Testing Panels for Epilepsy Good Start Genetics Introduces EmbryVu PGS Test 23andMe Secures FDA Approval for New Trimmed Down DNA-based Health Analysis Roche Rolls Out Oncology Assay AutoGenomics Launches INFINITI® SMART Transgenomic Rolls Out Transgenomic Leukodystrophy NGS Panel Color Genomics Rolls Out New Test for Cancer-Associated Genes PerkinElmer Launches Genetic Screening Processor® Instruments in China Mayo Clinic Launches Eight NGS Panels for Cardiac Disorders Sequenom Laboratories and Recombine Launch HerediT® UNIVERSAL Multipicom NV Launches ADH MASTR™ v2 assay 23andMe Launches Drug Development Unit Quest Diagnostics Launches Neurome™ Exome Sequencing Service Roche Launches cobas 6800/8800 Systems Agena Biosciences Launches MassARRAY 24-Well System FDA Grants Marketing Approval to 23andMe's DTC Bloom Syndrome Carrier Genetic Test Transgenomic to Launch ICE COLD-PCR™ Technology Rosetta Launches Sequencing-based Oncology Tests by Admera Health MedGenome Labs Launches Panorama Prenatal Test Ambry Genetics Launches CVD Genetic Testing Panels Exceltox Launches Pharmacogenomic Testing PerkinElmer Launches SCID Screening Test in North America Quest Diagnostics Introduces BRCAvantage Plus™ Genetic Technologies Launches BREVAGenplus Test Sophia Genetics Receives CE-IVD Certification for Genetic Testing Response Genetics Launches Immuno-Oncology Assay DeNA Life Science Launches Mycode Genetic Testing Service Pathway Genomics Launches BRCATrue™ Test Courtagen Launches Genetic Sequencing Tests for Neurodevelopmental Disorders Myriad Genetics Launches EndoPredict® Breast Cancer Test Assurex Health Expands GeneSight® Pharmacogenomic Testing Platform Illumina to Launch VeriSeq Embryo Screening Tool GENEWIZ Launches PGxOne™ Pharmacogenomic Test Ambry Genetics Launches ExomeNext™ and ExomeNext-Rapid™ Genetic Tests Pathway Genomics Launches Genetic Test to Detect Risk of Colorectal Cancer Mount Sinai Laboratory Develops Accurate Genetic Test for SMA 7. RECENT INDUSTRY ACTIVITY Agilent Inks Deal to Take Over Multiplicom DNA Diagnostics Center Acquires IDENTIGENE Genetic Analysis and Bio-Rad Ink Deal for Transferring Commercialization Rights to GA-map™ Thermo Fisher Files for PMA Approval of its Oncomine Universal Dx Test LabCorp Takes Over Sequenom WuXi AppTec and AutoGenomics Team Up to Launch Advanced Molecular Diagnostic Technology In China Danaher to Take Over Cepheid Quest Diagnostics to Offer Genetic Testing Services for Ancestry Transgenomic and LabCorp Sign Commercial License Agreement for TBIO's DNA Susceptibility Testing IP Next Biosciences Merges with Genesis Genetics PerkinElmer Expands Services in India PerkinElmer Takes Over Vanadis Diagnostics AutoGenomics and McKesson to Jointly Distribute INFINITI® Molecular Diagnostic Systems and Related Products Transgenomic Divests GAP Business Thermo Fisher Teams Up with Novartis and Pfizer for Developing NGS Oncology Test NeoGenomics Acquires Clarient MedGenome to Build Data Specific to India for Testing Kits Roche to Take Over Kapa Biosystems Natera Selects DNAnexus Cloud Genomics Platform for its Genetic Tests ESPERITE Acquires InKaryo Transgenomic Signs Agreement with Exiqon A/S Quest Diagnostics and Myriad Genetics End BRCA Gene Patent Litigation Roche to Acquire Majority Share of Foundation Medicine Roche Acquires Ariosa Diagnostics GSK Collaborates with GE on Oncology Genetic Testing Cancer Genetics to Acquire Gentris Corporation Natera Partners with Mount Sinai Genetic Testing Laboratory Transgenomic to Sell SURVEYOR Nuclease Technology to Integrated DNA Technologies Transgenomic Collaborates with Raptor Pharmaceuticals for Genetic Testing Services AutoGenomic Signs Agreement with Genomas Cancer Genetics Acquires BioServe Biotechnologies PerkinElmer to Close Its Signature Genomics Testing Business LifeLabs Medical Laboratory Services Buys out Centogene's Canadian Business CytoScan Dx Assay by Affymetrix Receives FDA Approval 8. FOCUS ON SELECT PLAYERS 23andMe, Inc. (USA) Abbott Laboratories (USA) AutoGenomics, Inc. (USA) Biocartis NV (Belgium) BioRad Laboratories (USA) Cepheid Inc. (USA) ELITech Group S.P.A. (France) Illumina, Inc. (USA) Laboratory Corporation of America Holdings (USA) Sequenom, Inc. (USA) Luminex Corporation (USA) Natera, Inc. (USA) PerkinElmer, Inc. (USA) QIAGEN N.V. (The Netherlands) Quest Diagnostics, Inc. (USA) Roche Diagnostics Corp. (Switzerland) Roche Molecular Diagnostics, Inc. (USA) Thermo Fisher Scientific (USA) Transgenomic, Inc. (USA) 9. GLOBAL MARKET PERSPECTIVE Table 24: World Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart) Table 25: World Historic Review for Genetic Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) Table 26: World 14-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart) III. MARKET 1. THE UNITED STATES A.Market Analysis The US: Leading Market for Genetic Testing Globally Demographic Changes Offer Growth Opportunities Table 27: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart) Burgeoning Potential for Genetic Testing Use of Genomic Data in Clinical Settings to Gather Pace Predictive Screening: Another Growth Area An important Market for Personalized Medicine Epidemic Proportion of Cancer in the US - Driver for Cancer Genetic Testing Table 28: New Cancer Cases by Gender and Affected Site in the US (2017E) (includes corresponding Graph/Chart) Table 29: Cancer Related Deaths by Gender in the US (2017E) (includes corresponding Graph/Chart) Newborn Testing Gains Ground Success Stories Skepticism Limits Widespread Adoption of Genetic Testing Favorable Reimbursement Policies Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing Popularity of Screening and ACOG Guidelines Sink Invasive Prenatal Diagnosis Numbers Tough Market Prospects for Sex Determination Tests Coverage of NIPT in Average Risk Pregnancies Expands Target Market Wastage from Unnecessary Genetic Testing - A Growing Concern IP Landscape of NIPD Tests US Patents of cff DNA-based NIPD Tests Direct-to-Consumer Testing - A Growing Market DTC Genetic Tests Provide POCT for Patients in Hospice Care Competitive Overview Myriad Eyes Diversification and Expansion for Growth Natera Holds Fort in the NIPT Market Table 30: Leading Players in the US Non-Invasive Prenatal Testing Market (2016): Percentage Breakdown of Revenue for Illumina, LabCorp/Sequenom, Natera, Roche and Others (includes corresponding Graph/Chart) Invitae Banks on Low Cost Solutions for Expanding Revenues Regulatory Environment Genetic Information Nondiscrimination Act Boosts Genetic Testing Stricter Regulations for DTC Genetic Testing H.R. 1313 Bill Rakes New Controversy FDA Attempts to Put a Leash around Unapproved DTC Genetic Tests Negotiated Prices Bring Comfort to Several Diagnostic Companies Product Launches Strategic Corporate Developments Select Key Players B.Market Analytics Table 31: The US Recent Past, Current & Future Analysis for Genetic Testing by Segment - Prenatal & Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Diagnostics Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart) Table 32: The US Historic Review for Genetic Testing by Segment - Prenatal & Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Diagnostics Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) Table 33: The US 14-Year Perspective for Genetic Testing by Segment - Percentage Breakdown of Revenues for Prenatal & Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Diagnostics Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart) 2. CANADA A.Market Analysis Current & Future Analysis Regulatory Scenario Rising Incidence of Chronic Diseases Spurs Genetic Testing Demand Table 34: New Cancer Cases in Canada (2016): Percentage Breakdown of Cancer Incidence by Gender and Affected Site (includes corresponding Graph/Chart) Table 35: New Cancer Cases in Canada by Province (2016) (includes corresponding Graph/Chart) Table 36: Cancer Incidence in Canada by Age Group and Gender: Age Standardized Incidence Rate per 100,000 People (2015) (includes corresponding Graph/Chart) Product Launches Strategic Corporate Development B.Market Analytics Table 37: Canadian Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart) Table 38: Canadian Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) 3. JAPAN A.Market Analysis Current & Future Analysis Demographics Drive Market Growth Table 39: Japanese Population by Age Group (2017) (includes corresponding Graph/Chart) DTC Genetic Testing Regulatory Scenario Product Launch B.Market Analytics Table 40: Japanese Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart) Table 41: Japanese Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) 4. EUROPE A.Market Analysis Market Overview An Insight into Molecular Diagnostics Markets in Europe Cancer Trends Table 42: Cancer Incidence in Europe by Site: 2012 (in Thousands) (includes corresponding Graph/Chart) Aging Population to Drive Demand for Genetic Testing Table 43: Population Breakup by Age Group for Select EU-28 Countries: 2015 (as a Percentage of Total Population) (includes corresponding Graph/Chart) European Personalized Medicine Market to Exhibit Robust Growth Legislations/Regulatory Policies in Select European Countries Legislations Governing Genetic Testing in Select European Countries B.Market Analytics Table 44: European Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart) Table 45: European Historic Review for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) Table 46: European 14-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart) 4a. FRANCE A.Market Analysis Current & Future Analysis Regulatory Environment in France Elitech Group S.P.A. - A Key Player B.Market Analytics Table 47: French Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart) Table 48: French Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) 4b. GERMANY A.Market Analysis Current & Future Analysis Parliamentary Regulations B.Market Analytics Table 49: German Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart) Table 50: German Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) 4c. ITALY Market Analysis Table 51: Italian Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart) Table 52: Italian Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) 4d. THE UNITED KINGDOM A.Market Analysis Current & Future Analysis Increased Support for Personalized Medicine to Drive Genetic Testing SMIP for Pharmacogenomic Testing Increasing Need for Less Risky Prenatal Diagnostic Methods in the UK Regulatory Scenario Non-consensual Analysis of DNA Made Illegal Principles for DTC Genetic Testing Laid out by HGC B.Market Analytics Table 53: The UK Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart) Table 54: The UK Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) 4e. REST OF EUROPE A.Market Analysis Current & Future Analysis Product Launches Strategic Corporate Developments Key Players B.Market Analytics Table 55: Rest of Europe Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart) Table 56: Rest of Europe Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) 5. ASIA-PACIFIC A.Market Analysis Current & Future Analysis Healthcare Spending in Asia-Pacific: On the Rise Select Regional Markets China China's FDA Curbs Prenatal Testing Genetic Testing to Reveal Real Talents in Children - A New Popular Application India Diagnostics Market in India Genomic Medicine - Nascent yet Promising Genetic Testing in India to Rise Australia and New Zealand Approval of Experiments on Human Embryos in New Zealand Product Launches Strategic Corporate Developments B.Market Analytics Table 57: Asia-Pacific Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart) Table 58: Asia-Pacific Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) 6. REST OF WORLD A.Market Analysis Current & Future Analysis Product/Service Launch Strategic Corporate Development B.Market Analytics Table 59: Rest of World Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart) Table 60: Rest of World Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 88 (including Divisions/Subsidiaries - 97) The United States (60) Canada (5) Japan (1) Europe (23) - France (2) - Germany (3) - The United Kingdom (2) - Spain (1) - Rest of Europe (15) Asia-Pacific (Excluding Japan) (5) Middle East (2) Africa (1) Read the full report: http://www.reportlinker.com/p02284877/Genetic-Testing.html About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. http://www.reportlinker.com __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-genetic-testing-industry-300477888.html


Patent
DNAnexus | Date: 2016-12-21

Disclosed herein are systems and methods for processing data, particularly biological data. An exemplary system comprises a memory and a processor coupled to the memory, wherein the memory comprises program instructions executable by the processor to: write into the memory a first index comprising one or more locations of a genomic sequence file comprising a header and genomic sequence data; calculate, based on the first index and a genomic range, a byte range of the genomic sequence file; write into the memory a portion of the genomic sequence file, wherein the portion comprises genomic sequence data located within the byte range; calculate a second index; and write into the memory the second index, wherein the genomic sequence data are compressed and no portion of the genomic sequence data is decompressed.


News Article | June 19, 2017
Site: www.prnewswire.com

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Genetic Testing in US$ Million. The US market is further analyzed by the following Segments: The report profiles 88 companies including many key and niche players such as: Key Topics Covered: 1. GLOBAL MARKET OVERVIEW A Curtain Raiser Top Ten Genetic Disorders Worldwide Genetic Testing: Heralding a New Era Genetic Testing Paves the Way for Personalized Medicine Genetic Testing A Critical Part of the Rapidly Developing In-Vitro Diagnostics (IVD) Market Genetic Testing: The Rapidly Growing Segment of Molecular Diagnostics Market An Overview of Current Technologies in Genetic Testing Biomarker Discovery Leads to Advanced Genetic Testing List of US-FDA Approved Biomarkers for Cancer Ballooning Global Population Offers Increased Growth Opportunities Aging Population Drives the Genetic Testing Market Improving Healthcare Expenditure to Drive Demand 2. SEGMENTAL REVIEW Prenatal Testing Market to Rise List of Genetic Disorders by Event, Genetic Manifestation and Prevalence Prenatal Testing Changing the World of Pregnancy Care Prenatal Testing A Rudimentary Overview List of Available Prenatal Screening and Diagnostic Tests by Indication Conventional Invasive Pre-Natal Diagnostic Techniques A Risky Affair Other Negativities of Existing Invasive Techniques Emergence of Non-Invasive Prenatal Diagnosis (NIPD) US Leads in NIPD Market Competition Intensifies in the NIPD Market Commercially Available NIPD (Genetic) Tests for Aneuploidy in the US NIPD Eliminates Risks and Uncertainty of Conventional Diagnostic Procedures Opposition to NIPD Technique A Significant Hurdle to Adoption Benefits Outweigh Snags in NIPD Tests Major Factors Influencing Penetration of NIPD Tests Diversity in NIPD Usage on the Cards Expanded Newborn Screening Technological Advancements Boost Prenatal Genetic Screening Market CMA Stakes Claim as the First-Line Test in Fetal Abnormalities; Issues Hinder Growth Strain on Resources Prevent Wide Adoption of Expanded Carrier Sequencing Fetal Diagnostic WES A Promising Advancement in Prenatal Screening Predictive Diagnostics Breast Cancer Gene Testing Market to Expand Strongly Myriad Genetics The Unquestioned Leader in Breast Cancer Testing Routine Clinical Testing Vs. Predictive Genetic Testing Increasing Incidence and Prevalence of CDDs: A Major Growth Driver Discovery of Novel Biomarkers Crucial to Predictive Diagnostics Unresolved Issues Hamper Widespread Implementation of Genetic Diagnosis and Testing for Monogenetic Disease Dearth of Genetic Counselors A Major Hurdle for the Predictive Genetic Testing Pharmacogenomics Development Augurs Growth of Genetic Testing Market 3. MARKET TRENDS Direct-to-Consumer Genetic Testing A Key Trend in the Genetic Testing Market Direct-to-Consumer Genetic Testing is Here to Stay Creating a Platform for New Companies Business Models for DTC Genetic Testing Firms Growing Prominence of DTC Genetic Testing: A Boon or a Curse? Genetic Screening of Newborns to Rise Pre-implantation Genetic Diagnosis (PGD) A Major Driver for the Genetic Testing Market Whole Genome Sequencing Boon or Bane to Genetic Testing? Utility of Genetic Testing for Warfarin Study As Technologies Grow, Need for Better Interpretation of Tests Increases Selling Collected Patient Genetic Information Becomes a New Business Oncology A Key Focus Area for Genetic Testing Liquid Biopsy to Change the Face of Cancer Diagnosis and Treatment Genetic Testing May Aid CNS Disease Therapeutics Neurodegenerative Diseases Major Focus Area for Genetic Testing Alzheimer's Disease Validity of Emerging Genetic Tests for Alzheimer's Newly Developed Test Predicts Age of Onset of Alzheimer's Huntington's Disease Genetic Testing An Indispensable Tool for Cystic Fibrosis Histocompatibility Testing Next-Generation Sequencing A Giant Leap in Genome Sequencing Pediatric Genetic Testing for Screening Adult Onset Disorders Fast Gaining Acceptance Better Regulatory Safeguards Required for Global Genetic Testing Industry Challenges Faced Controversial Applications Marr Genetic Testing Market Genetic Counseling: Gaining Momentum Online Approach Gains Momentum Recommendations of ACOG and ACGM Augments Demand for Cystic Fibrosis Testing Ethical Issues & Need for Appropriate Regulating Policies Issues Related to Genetic Tests for Obesity Diagnosis and Treatment during Pregnancy An Effective Way of Alleviating Syphilis Related Deaths and Stillbirths 4. MOLECULAR DIAGNOSTICS MARKET - AN INSIGHT Global Molecular Diagnostics on a High Growth Curve Automation Driving Global Market Molecular Diagnostics: Marking the Convergence of Numerous Technologies MDx Market for Infectious Diseases Zooming Ahead Aging Population, Disease Incidence Fundamental Drivers of Growth Pharmaceutical Firms Carving Their Niche in Molecular Diagnostics Market Towards Tailoring the Right Treatment for the Right Disease Limited Reimbursements by Third Party Payers A Stumbling Block Disease-Specific Molecular Diagnostics to Deliver Improved Clinical Outcomes Molecular Diagnostics and Intellectual Property Business Opportunities in the Offing Medical Training and Practice Challenges Hurdles All the Way for Companies Eyeing Molecular Diagnostics Product Marketing Key to Commercial Success Integration of Molecular Diagnostics into Therapeutics Molecular Diagnostics Moving from Centralization to Decentralization Competitive Landscape of the Molecular Diagnostics Market New Entrants Eye Unmet Needs 5. PRODUCT OVERVIEW Preface to Genetic Testing Genetic Testing and its Applications Gene Candidate and Genome Screen DNA Chip' to Chip into Genetic Field Techniques Used to Identify Changes in Genes Types of Genetic Testing Prenatal Diagnosis Cancer Testing Carrier Identification Newborn Screening Predictive Testing Pre-Symptomatic Testing Cytogenetic Tests Steps in Genetic Testing Process Limitations Risks and Other Limitations of Genetic Testing Medical Institutions to Reap the Benefit of Genetic Testing Pharmacogenetics/Pharmacogenomics Review of Select Genetic Tests Cystic Fibrosis Breast and Ovarian Cancer (BRCA) Alzheimer's disease Colorectal Cancer Haemochromatosis (HH) Cowden Syndrome Huntington's disease (HD) Costs of Select Tests Genetic Testing Techniques Signal Amplification Technologies PCR New Developments Quantitative Real-Time PCR for Molecular Diagnostics Signal Detection and Quantification Quantitative Real-Time RT-PCR Analysis Applications of Quantitative Real-Time PCR Analysis Viral Detection and Viral-Load Monitoring Sensitive Detection of Infectious Disease Agents Predisposition Testing Non-PCR Methods Other Signal Amplification Technologies DNA Probe Based Products Direct Detection of Specific Nucleic Acid Sequences Nucleic Acid Amplification and Detection DNA Sequencing and Gene Detection Arrays of Immobilized Probes (DNA Chips) in Gene Detection RNA Diagnostics 6. PRODUCT LAUNCHES/INNOVATIONS AutoGenomics Rolls Out INFINITI® H. pylori Assay 23andMe Obtains FDA Approval for Personal Genetic Test for Select Diseases Invitae Adds News Tests to Proactive Genetic Testing Repertoire Thermo Fisher Scientific Launches CarrierScan Assay MedGenome Unveils Claria Carrier Screening Test in India Phosphorus Rolls Out Advances Tests for Inherited Conditions Cancer Genetics Launches Genomic Panel for HBOC Illumina, Bio-Rad Launch Single-Cell Genomic Sequencing Solution MyHeritage Introduces MyHeritage DNA Service Thermo Fisher Scientific Unveils Clariom Pico Assays IBM Watson Health, Quest Diagnostics Roll Out IBM Watson Genomics Thermo Fisher Scientific Introduces PharmacoScan Solution Good Start Genetics Launches EmbryVu PGS Test Spark Therapeutics Introduces Testing for Inherited Retinal Diseases AutoGenomics Launches INFINITI® Buccal Sample Collection Kit FutuTest Launches FERTIFY Genetic Test Quest Diagnostics Introduces New Cancer Test Services Good Start Genetics Launches Next-Generation Embryo Screening Solution Invitae Introduces Pediatric Tests for Rare Disease and Pediatric Genetics Contextual Genomics Introduces Cancer Genome Test Transgenomic Introduces CMT NGS Panel Ambry Genetics Rolls Out Suite of Genetic Testing Panels for Epilepsy Good Start Genetics Introduces EmbryVu PGS Test 23andMe Secures FDA Approval for New Trimmed Down DNA-based Health Analysis Roche Rolls Out Oncology Assay AutoGenomics Launches INFINITI® SMART Transgenomic Rolls Out Transgenomic Leukodystrophy NGS Panel Color Genomics Rolls Out New Test for Cancer-Associated Genes PerkinElmer Launches Genetic Screening Processor® Instruments in China Mayo Clinic Launches Eight NGS Panels for Cardiac Disorders Sequenom Laboratories and Recombine Launch HerediT® UNIVERSAL Multipicom NV Launches ADH MASTR v2 assay 23andMe Launches Drug Development Unit Quest Diagnostics Launches Neurome Exome Sequencing Service Roche Launches cobas 6800/8800 Systems Agena Biosciences Launches MassARRAY 24-Well System FDA Grants Marketing Approval to 23andMe's DTC Bloom Syndrome Carrier Genetic Test Transgenomic to Launch ICE COLD-PCR Technology Rosetta Launches Sequencing-based Oncology Tests by Admera Health MedGenome Labs Launches Panorama Prenatal Test Ambry Genetics Launches CVD Genetic Testing Panels Exceltox Launches Pharmacogenomic Testing PerkinElmer Launches SCID Screening Test in North America Quest Diagnostics Introduces BRCAvantage Plus Genetic Technologies Launches BREVAGenplus Test Sophia Genetics Receives CE-IVD Certification for Genetic Testing Response Genetics Launches Immuno-Oncology Assay DeNA Life Science Launches Mycode Genetic Testing Service Pathway Genomics Launches BRCATrue Test Courtagen Launches Genetic Sequencing Tests for Neurodevelopmental Disorders Myriad Genetics Launches EndoPredict® Breast Cancer Test Assurex Health Expands GeneSight® Pharmacogenomic Testing Platform Illumina to Launch VeriSeq Embryo Screening Tool GENEWIZ Launches PGxOne Pharmacogenomic Test Ambry Genetics Launches ExomeNext and ExomeNext-Rapid Genetic Tests Pathway Genomics Launches Genetic Test to Detect Risk of Colorectal Cancer Mount Sinai Laboratory Develops Accurate Genetic Test for SMA 7. RECENT INDUSTRY ACTIVITY Agilent Inks Deal to Take Over Multiplicom DNA Diagnostics Center Acquires IDENTIGENE Genetic Analysis and Bio-Rad Ink Deal for Transferring Commercialization Rights to GA-map Thermo Fisher Files for PMA Approval of its Oncomine Universal Dx Test LabCorp Takes Over Sequenom WuXi AppTec and AutoGenomics Team Up to Launch Advanced Molecular Diagnostic Technology In China Danaher to Take Over Cepheid Quest Diagnostics to Offer Genetic Testing Services for Ancestry Transgenomic and LabCorp Sign Commercial License Agreement for TBIO's DNA Susceptibility Testing IP Next Biosciences Merges with Genesis Genetics PerkinElmer Expands Services in India PerkinElmer Takes Over Vanadis Diagnostics AutoGenomics and McKesson to Jointly Distribute INFINITI® Molecular Diagnostic Systems and Related Products Transgenomic Divests GAP Business Thermo Fisher Teams Up with Novartis and Pfizer for Developing NGS Oncology Test NeoGenomics Acquires Clarient MedGenome to Build Data Specific to India for Testing Kits Roche to Take Over Kapa Biosystems Natera Selects DNAnexus Cloud Genomics Platform for its Genetic Tests ESPERITE Acquires InKaryo Transgenomic Signs Agreement with Exiqon A/S Quest Diagnostics and Myriad Genetics End BRCA Gene Patent Litigation Roche to Acquire Majority Share of Foundation Medicine Roche Acquires Ariosa Diagnostics GSK Collaborates with GE on Oncology Genetic Testing Cancer Genetics to Acquire Gentris Corporation Natera Partners with Mount Sinai Genetic Testing Laboratory Transgenomic to Sell SURVEYOR Nuclease Technology to Integrated DNA Technologies Transgenomic Collaborates with Raptor Pharmaceuticals for Genetic Testing Services AutoGenomic Signs Agreement with Genomas Cancer Genetics Acquires BioServe Biotechnologies PerkinElmer to Close Its Signature Genomics Testing Business LifeLabs Medical Laboratory Services Buys out Centogene's Canadian Business CytoScan Dx Assay by Affymetrix Receives FDA Approval 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 88 (including Divisions/Subsidiaries 97) For more information about this report visit https://www.researchandmarkets.com/research/7h8x42/genetic_testing Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-2017-genetic-testing-strategic-business-report---research-and-markets-300475749.html


A computer application programming interface (API) for interacting with genomic data. Genomic data is stored by a genomic information provider using cloud-optimized, tabular structures in the form of genomic tables. A client computer may instruct, via API method calls, the genomic information provider to create a genomic table. Client computers may add genomic data to the genomic table via additional API method calls. A client computer may close the genomic table via an API method call. Once closed, client computers may retrieve genomic data based on genomic coordinates from the genomic table via API method calls. In this way, the transmission of genomic data via flat files can be avoided.


Patent
DNAnexus | Date: 2014-03-03

An ensemble predictor for characterizing uncharacterized genetic mutations is disclosed. A first set of genomic information representing a particular (e.g., harmful) mutation is obtained. The first set of genomic information is provided to a number of underlying mutation impact predictors. Predictions are obtained from the underlying predictors. The predictions predict whether the first set of genomic information represents the particular mutation. The predictions and the particular (known) mutation are provided to a logistic regression model, which provides a coefficient for each underlying predictor. A second set of (uncharacterized) genomic information is obtained. The second set of genomic information is provided to the underlying predictors. Predictions are obtained from the underlying predictors and are then weighted using the coefficients. A characterization (e.g., as harmful or not) of the second set of genomic information is provided by the ensemble predictor based on the weighted underlying predictions and may be displayed.


Patent
DNAnexus | Date: 2012-08-10

A repository of DNA sequence data is available online. A user can query the repository using a search term. Search results that are provided by the repository include information about studies, experiments, samples, and/or runs that are related to the search term. A user can select one or more of the displayed search results. Based on the user selection, the repository provides relationship(s) between the selected results and run(s). Runs may be associated with DNA sequence data. The determined relationship between the search term and any available DNA sequence data is displayed. The DNA sequence data may be obtained by the user using, for example, the FASTQ format and/or the SRA format.

Loading DNAnexus collaborators
Loading DNAnexus collaborators